Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 4Thoracic 2Gastrointestinal 2Tumor-Agnostic 1Sarcoma 1Genitourinary 1Dermatologic 1Breast 1

Conditions

Neurofibrosarcoma 1Neurofibromatosis 1 1

Interventions

Specimen Handling 14Magnetic Resonance Spectroscopy 14Doxorubicin 11Cyclophosphamide 11Biopsy 9Radiation 8atezolizumab 7Temozolomide 7X-Rays 6Vincristine 6Nivolumab 6Etoposide 6Bevacizumab 6liposomal doxorubicin 5fludarabine 5cabozantinib 5Sirolimus 5Radiotherapy 5Phantoms, Imaging 5Irinotecan 5Immunoglobulin G 5Ifosfamide 5Disulfides 5pembrolizumab 4Nuclear Medicine Department, Hospital 4temsirolimus 3palbociclib 3olaparib 3fludarabine phosphate 3Surgical Procedures, Operative 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
AZD 6244 × Sarcoma × 30 days × Clear all
NCT03433183 2026-05-27

SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors

Sarcoma Alliance for Research through Collaboration

Phase 2 Completed
21 enrolled 12 charts
CNSSarcoma

Neurofibromatosis 1, Neurofibrosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡